H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

UnitedHealth Group announces its revenues and net earnings in 2009

UnitedHealth Group today reported growth in revenues and net earnings per share in 2009. The Company earned $0.81 per share in the fourth quarter, bringing full year 2009 net earnings to $3.24 per share.

21 Jan 2010

ETMC Athens effectively handles record number of H1N1 cases

Throughout the month of September, East Texas Medical Center Athens (ETMC Athens) has seen a 42% average increase in number of patients per day and is taking it in stride. Improved efficiencies in the Emergency Department facilitated by a process improvement firm, Compirion Healthcare, have allowed the hospital to absorb the volume and see an improvement in quality.

21 Jan 2010

Sinovac Biotech announces financial update, new joint ventures and developments

Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, today announced the following recent developments.

21 Jan 2010

SVA plans to sell 8,650,000 common shares in an underwritten public offering

Sinovac Biotech Ltd. ( SVA), a leading China-based vaccine manufacturer, today announced that it plans to sell, subject to market and other conditions, 8,650,000 common shares of the company in an underwritten public offering.

21 Jan 2010

Covidien announces results for first-quarter of fiscal 2010

Covidien plc today reported results for the first quarter of fiscal 2010 (October – December 2009). First-quarter net sales of $2.7 billion were up 7% from the $2.6 billion reported a year ago, with favorable foreign exchange of $121 million increasing the quarterly sales growth rate by approximately 5 percentage points.

20 Jan 2010

Researchers develop more effective way to predict the spread of foot-and-mouth disease

Combining technology and animal health, a group of Kansas State University researchers is developing a more effective way to predict the spread of foot-and-mouth disease and the impact of preventative measures.

20 Jan 2010

WHO, CDC issue H1N1 updates

Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.

19 Jan 2010

Sirnaomics certifies polypeptide nanoparticle technology

Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School.

18 Jan 2010

Margaret A. Hamburg thanks America's health care professionals on H1N1 vaccine safety

FDA Commissioner Margaret A. Hamburg today sent a letter to America's health care professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on safety monitoring of the 2009 H1N1 vaccines.

18 Jan 2010

Health Policy Research Roundup: New Orleans clinic experiences, health reform and lagging biomedical research funds

Journal of the American Medical Association: Funding of US Biomedical Research, 2003-2008 - After doubling in a decade, the rate of increase in biomedical research in the U.S. has slowed since 2005, and the level of funding from the National Institutes of Health and industry appears to have decreased by 2 percent in 2008, after adjusting for inflation, the authors of this study report.

18 Jan 2010

Large number of infected cases in Australia attribute to failure in containing H1N1 pandemic

The rapid and widespread entry of the pandemic H1N1 infection that led to a large number of infected cases in Australia suggested a public health management failure in containing the pandemic when it broke out in April 2009.

18 Jan 2010

Scientists develop alternative method for producing active ingredient in Tamiflu

Scientists have developed an alternative method for producing the active ingredient in Tamiflu-, the mainstay for fighting H1N1 and other forms of influenza. The new process could expand availability of the drug by reducing its cost, which now retails for as about $8 per dose.

18 Jan 2010

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

18 Jan 2010

WHO official rejects claims agency overhyped threat of H1N1

Keiji Fukuda, the special adviser to the WHO director general on pandemic influenza, on Thursday dismissed allegations that the agency exaggerated the threat of the H1N1 (swine flu) pandemic and has been influenced by the pharmaceutical industry, the Washington Post reports.

18 Jan 2010

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan.

13 Jan 2010

Whitley urges public to get vaccinated against H1N1 influenza virus

With several months left in the influenza season and growing supplies of vaccine, now is an opportune time to get vaccinated against the 2009 H1N1 influenza virus, says Richard Whitley, M.D., director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases and current president of the Infectious Diseases Society of America (IDSA).

13 Jan 2010

New genetic evidence can improve avian influenza surveillance programs

Genetic analyses of avian influenza in wild birds can help pinpoint likely carrier species and geographic hot spots where Eurasian viruses would be most likely to enter North America, according to new U.S. Geological Survey research.

13 Jan 2010

Record-breaking 8,300 health care professionals participate in online H1N1 vaccination education program

A record-breaking 8,300 front-line health care professionals participated in an accredited, online education program about H1N1 vaccination in November 2009 alone.

13 Jan 2010

Send Word Now to provide emergency voice and text communication services to Unity Health System's hospitals

Send Word Now, the leading provider of emergency notification and on-demand alerting and response services, announced today that Unity Health System, a 681-bed health-care network based out of Rochester, New York, has selected Send Word Now to provide emergency voice and text communication services to its hospitals.

13 Jan 2010

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

moksha8 and BioCryst today announced that moksha8 has been granted approval from COFEPRIS (The Federal Commission for the Protection against Sanitary Risk) in Mexico for the importation and use of peramivir in patients with influenza associated with the 2009 H1N1 influenza A strain.

13 Jan 2010

H1N1 News and Research

UnitedHealth Group announces its revenues and net earnings in 2009

ETMC Athens effectively handles record number of H1N1 cases

Sinovac Biotech announces financial update, new joint ventures and developments

SVA plans to sell 8,650,000 common shares in an underwritten public offering

Covidien announces results for first-quarter of fiscal 2010

Researchers develop more effective way to predict the spread of foot-and-mouth disease

WHO, CDC issue H1N1 updates

Sirnaomics certifies polypeptide nanoparticle technology

Margaret A. Hamburg thanks America's health care professionals on H1N1 vaccine safety

Health Policy Research Roundup: New Orleans clinic experiences, health reform and lagging biomedical research funds

Large number of infected cases in Australia attribute to failure in containing H1N1 pandemic

Scientists develop alternative method for producing active ingredient in Tamiflu

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

WHO official rejects claims agency overhyped threat of H1N1

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

Whitley urges public to get vaccinated against H1N1 influenza virus

New genetic evidence can improve avian influenza surveillance programs

Record-breaking 8,300 health care professionals participate in online H1N1 vaccination education program

Send Word Now to provide emergency voice and text communication services to Unity Health System's hospitals

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News